Jefferies reiterates Erasca stock Buy rating ahead of ASCO data

Jefferies reiterated a Buy on Erasca with a $21 price target versus the current $20.40 share price, citing ERAS-0015 phase I data as a potential inflection point at ASCO 2026. The stock has surged more than 1,500% in the past year to a $6.35 billion market cap, while the company also reported a $29.1 million Q4 2025 net loss and a $124.6 million full-year loss. Recent catalysts include expanded worldwide rights to ERAS-0015 and additional bullish analyst price-target increases.

Analysis

ERAS is now trading less like a single-asset biotech and more like a financed call option on RAS-space credibility. The market is implicitly pricing a binary readout into a much larger platform takeout narrative, which means any data that looks merely “good” can still support upside if it preserves the possibility of combination use and competitive differentiation. The key second-order effect is that the stock’s move will likely be driven less by absolute efficacy and more by whether investors believe the asset can avoid being boxed into a narrow monotherapy niche.

The main losers in a strong ERAS print are not just direct oncology peers, but any late-stage RAS program whose story depends on clean differentiation rather than broad combinability. If ERAS shows a tolerability edge with enough activity to matter, it pressures valuation multiples across the space because it raises the bar for how much safety improvement is required to justify premium pricing in a crowded class. That matters because the market is currently rewarding optionality on strategic interest; a credible alternate could compress takeover expectations across the group.

The risk setup is asymmetric but event-heavy: the next catalyst window is measured in months, not days, and the downside is sharper if data land in the “active but not obviously best-in-class” zone. In that middle case, the stock can de-rate quickly because the market has already moved well ahead of fundamentals, while burn and dilution remain real constraints. The most important reversal trigger is not outright failure — it is a dataset that is merely adequate and fails to justify either premium partnering interest or a near-term rerating.

The contrarian read is that consensus may be underestimating how much of the move is now driven by scarcity value in RAS oncology rather than de-risked clinical fundamentals. That usually works until the first true comparator-quality dataset arrives, at which point winners and losers separate very fast. In that sense, ERAS is less a clean long than a catalyst-trading vehicle with a high volatility regime and a narrow path to outperforming already elevated expectations.

Key Decisions for Investors

• Maintain a tactical long ERAS into the next major clinical catalyst only if size is capped; treat it as a 4-8 week event trade with upside to a multiple expansion, but assume 20-30% drawdown risk on any merely adequate data.
• Pair trade: long ERAS / short a basket of later-stage RAS competitors with less differentiated safety profiles over the next 1-3 months to isolate relative read-through risk rather than taking pure single-name beta.
• Use call spreads rather than outright stock for ERAS ahead of the conference window; structure for 2-3x payoff if the readout is clearly differentiated, while limiting downside if the market sells the news.
• If ERAS gaps sharply on the catalyst, trim into strength on the first 15-20% move unless the data establish both efficacy and tolerability separation; the stock likely prices strategic optionality faster than fundamentals can catch up.
• Watch for financing / dilution risk over the next 6-12 months; if the company uses post-catalyst strength to raise capital, fade extended upside rather than chase it.